Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | BUB1 | O43683 | 1/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | PAK4 | O96013 | 1/20 | 0.66 |
| ▸ | ROS1 | P08922 | 1/20 | 0.66 |
| ▸ | AXL | P30530 | 1/20 | 0.66 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.66 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.66 |
| ▸ | MERTK | Q12866 | 1/20 | 0.66 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.66 |
| ▸ | PAK6 | Q9NQU5 | 1/20 | 0.66 |
| ▸ | PAK5 | Q9P286 | 1/20 | 0.66 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14839039 | 0.85 | SYK (0.69) | SYKKCNH2BUB1JAK2PAK4 | |
| SCHEMBL14839040 | 0.80 | SYK (0.68) | SYKKCNH2BUB1JAK2PAK4 | |
| SCHEMBL14838995 | 0.80 | SYK (0.69) | SYKKCNH2BUB1JAK2PAK4 | |
| SCHEMBL16253414 | 0.79 | SYK (0.82) | SYKKCNH2 | |
| SCHEMBL14838991 | 0.79 | SYK (0.69) | SYKKCNH2BUB1JAK2PAK4 | |
| SCHEMBL15389179 | 0.79 | SYK (1.00) | SYKKCNH2BUB1JAK2PAK4 | |
| SCHEMBL14838987 | 0.79 | SYK (0.69) | SYKKCNH2BUB1JAK2PAK4 | |
| SCHEMBL14839245 | 0.79 | SYK (0.69) | SYKKCNH2BUB1JAK2PAK4 | |
| SCHEMBL15388836 | 0.78 | SYK (1.00) | SYKKCNH2BUB1JAK2PAK4 | |
| SCHEMBL14839013 | 0.78 | SYK (0.70) | SYKKCNH2BUB1JAK2PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | SYK, BTK, JAK2 | SYK 1/4885KCNH2 146/4885BUB1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.